MARRONE BIO INNOVATIONS INC

Form SC 13G February 13, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.)*

Marrone Bio Innovations, Inc.

(Name of Issuer)

Common stock, \$0.00001 par value per share (Title of Class of Securities)

57165B106 (CUSIP Number)

December 31, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

oRule 13d-1(b)

oRule 13d-1(c)

ýRule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 57165B106

NAMES OF REPORTING PERSONS

1. Syngenta Ventures Pte. Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2. (a) c

(b) o

SEC USE ONLY

3.

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

Singapore

SOLE VOTING POWER

5.

1,889,877*

SHARED VOTING POWER

6. 0

SOLE DISPOSITIVE POWER

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

1,889,877*

SHARED DISPOSITIVE POWER

8. 0

AGGREGATE AMOUNT BENEFICIALLY OWNED

9. BY EACH REPORTING PERSON

1,889,877*

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE 10.

0

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

9.84%**

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12.

CO

^{*} The shares reported do not include 315,200 shares and 16,827 shares that were sold by the Reporting Person on February 11, 2014 and February 12, 2014, respectively.

^{**} This percentage is calculated based upon 19,207,690 shares of the issuer's common stock outstanding as of November 1, 2013, as set forth in the issuer's Form 10-Q for the period ended September 30, 2013, filed with the Securities and Exchange Commission on November 8, 2013.

Page 2 of 5 Pages

Item 1. (a) Name of Issuer:
Marrone Bio Innovations, Inc.
(b) Address of Issuer's Principal Executive Offices:
2121 Second St. Suite A-107, Davis, CA 95618
Item 2. (a) Name of Person Filing:
Syngenta Ventures Pte. Ltd.
(b) Address of Principal Office or, if none, Residence:
1, Harbourfront Avenue #03-03, Keppel Bay Tower, Singapore 098632
(c) <u>Citizenship or Place of Organization</u> :
Singapore
(d) <u>Title of Class of Securities</u> :
Common stock
(e) <u>CUSIP Number</u> :
57165B106
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
(b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

Investment Company Act of 1940 (15 U.S.C. 80a-3);

(i)

(j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); and
(k) o Group, in accordance with §240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Page 3 of 5 Pages

Item 4. Ownership.

- (a) Amount beneficially owned: 1,889,877*
- (b) Percent of class: 9.84%**
- * The shares reported do not include 315,200 shares and 16,827 shares that were sold by the Reporting Person on February 11, 2014 and February 12, 2014, respectively.
- ** This percentage is calculated based upon 19,207,690 shares of the issuer's common stock outstanding as of November 1, 2013, as set forth in the issuer's Form 10-Q for the period ended September 30, 2013, filed with the Securities and Exchange Commission on November 8, 2013.
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote: 1,889,877*
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 1,889,877*
- (iv) Shared power to dispose or to direct the disposition of: 0
- Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable

Item <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the</u>
 Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

Item 10. Certifications.

Not applicable

Page 4 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2014

SYNGENTA VENTURES PTE. LTD.

By:/s/ Alexander Steel Name: Alexander Steel

Title: Director

Page 5 of 5 Pages